NCCN 2020 Virtual Congress: Hematologic Malignancies™

October 9, 2020 to October 10, 2020

The treatment of hematologic malignancies has become increasingly complex as a result of the rapid pace and number of advances in the biology and treatment of hematologic malignancies and the numerous novel drugs that have been approved or are in development, many with novel mechanisms of action. Clinicians who manage patients with hematologic malignances are challenged to stay abreast of advances in the evolving diagnostic and treatment landscape to ensure optimal patient outcomes.

The NCCN 2020 Virtual Congress: Hematologic Malignancies™ will focus on updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), new, emerging and novel therapeutic agents, advances in cancer care, and the practical management of patients with hematologic malignancies.

Registration

Agenda

Target Audience

This educational program is designed to meet the educational needs of oncologists, hematologists, nurse practitioners, nurses, pharmacists, physician assistants, and other health care professionals who manage patients with hematologic malignancies.

Learning Objectives

The ultimate goal for NCCN continuing education is to change patient outcomes by improving the competence and performance of clinicians.  The goal of the NCCN 2020 Virtual Congress: Hematologic Malignancies™ is to ensure that members of the interprofessional oncology care team, including physicians, nurse practitioners, nurses, physician assistants, pharmacists, and other relevant health care professionals, have the knowledge and skills necessary to:

  • Apply the current standards of oncology care and key updates in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) to optimize the management of patients with various hematologic malignancies.
  • Review new, emerging, and novel therapeutic agents and treatment strategies and incorporate these into the management of patients with hematologic malignancies.
  • Communicate with members of the interprofessional oncology care team to improve collaborative performance in the management of patients with hematologic malignancies.

A detailed list of learning objectives by session topic is available here.

Additional information
Supporters: 

This activity is supported by educational grants from: 

  • AstraZeneca
  • Bayer Healthcare Pharmaceuticals
  • Daiichi Sankyo
  • GlaxoSmithKline
  • Jazz Pharmaceuticals, Inc.
  • Novartis
  • Pharmacyclics LLC, an Abbvie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
  • Pfizer Inc.
  • Seattle Genetics, Inc. 
  • Takeda

This activity is supported by independent educational grants from:

  • Abbvie
  • Astellas
  • Incyte

This activity is supported by an independent medical education grant from Bristol Myers Squibb.

Course summary
Available credit: 
  • 6.50 AAPA Category 1 CME credit
  • 6.50 ABIM MOC
  • 6.50 ACPE contact hours
  • 6.50 AMA PRA Category 1 Credit™
  • 6.50 ANCC contact hours
  • 6.50 Participation
Course opens: 
10/07/2020
Course expires: 
01/10/2021
Event starts: 
10/09/2020 - 11:30am
Event ends: 
10/10/2020 - 3:30pm
Cost:
$0.00

NCCN Medical Education Disclosure Policy

It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics). 

Per the ACCME Standards for Commercial Support, individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. A complete list of individuals’ relationships with external entities is available upon request.

Definitions 

NCCN continuing education considers financial relationships to create a “conflict of interest” when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship.

NCCN continuing education considers “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship.

Faculty Disclaimers

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.

Faculty Disclosures

The faculty listed below discloses no relevant financial relationships:

Natalie S. Callander, MD

The faculty listed below discloses the following relevant financial relationships:

Ranjana H. Advani, MD
ADC Therapeutics: Consulting Fee
Celgene Corporation: Consulting Fee
Forty Seven, Inc.: Grant/Research Support
Genentech, Inc./Roche Laboratories, Inc.: Consulting Fee; Grant/Research Support; Scientific Advisor
Gilead Sciences, Inc.: Consulting Fee; Grant/Research Support; Scientific Advisor
Janssen Pharmaceutica Products, LP: Grant/Research Support
Kura Oncology, Inc.: Grant/Research Support
Merck & Co., Inc.: Grant/Research Support
Millennium Pharmaceuticals, Inc.: Grant/Research Support
Portola Pharmaceuticals, Inc.: Consulting Fee
Regeneron Pharmaceuticals, Inc.: Grant/Research Support
sanofi-aventis U.S.: Consulting Fee
Seattle Genetics, Inc.: Consulting Fee; Grant/Research Support; Scientific Advisor
Takeda Pharmaceuticals North America, Inc.: Consulting Fee; Scientific Advisor

Patrick A. Brown, MD
Aptitude Health: Honoraria
Jazz Pharmaceuticals Inc.: Consulting Fee
Novartis Pharmaceuticals Corporation: Consulting Fee; Honoraria
Servier: Consulting Fee

Aaron T. Gerds, MD, MS
Celgene Corporation: Consulting Fee; Grant/Research Support
Constellation: Scientific Advisor
CTI BioPharma Corp.: Grant/Research Support
Galecto: Scientific Advisor
Imago Biosciences: Grant/Research Support
Incyte Corporation: Grant/Research Support
Kartos: Scientific Advisor
PharmaEssentia: Scientific Advisor
Promedior, Inc.: Scientific Advisor
Sierra: Grant/Research Support 

Leo I. Gordon, MD
Celgene Corporation: Grant/Research Support
Gilead Sciences, Inc.: Scientific Advisor
Juno Therapeutics, Inc.: Grant/Research SupportZylem Biosciences: Ownership/Partnership/Principal 

Jens Hillengass, MD
Adaptive Biotech: Honoraria
Bristol-Myers Squibb Company: Honoraria
Curio Science: HonorariaJanssen Pharma
GlaxoSmithKline: Honoraria
Janssen Pharmaceutica Products, LP: Honoraria
ONCOtracker, Inc.: Honoraria
Rapid Payer Response: Honoraria
Research to Practice: Honoraria
Xian Janssen: Honoraria

Steven Horwitz, MD
ADC Therapeutics: Grant/Research Support 
Aileron Therapeutics, Inc.: Grant/Research Support
Astex Pharmaceuticals: Consulting Fee
C4 Therapeutics: Consulting Fee
Celgene Corporation: Consulting Fee; Grant/Research Support
Corvus Pharmaceuticals: Grant/Research Support
Daiichi-Sankyo Co.: Grant/Research Support
Forty Seven, Inc.: Grant/Research Support
Janssen Pharmaceutica Products, LP: Consulting Fee
Kura Oncology, Inc.: Consulting Fee
Kyowa Hakko Kirin Co., Ltd.: Consulting Fee
Myeloid Therapeutics: Consulting Fee
Portola Pharmaceuticals, Inc.: Grant/Research Support
Seattle Genetics, Inc.: Consulting Fee; Grant/Research Support
Takeda Pharmaceuticals North America, Inc.: Consulting Fee
Trillium Therapeutics Inc.: Grant/Research Support
Verastem Oncology: Consulting Fee; Grant/Research Support

Eric Hsi, MD
AbbVie, Inc.: Grant/Research Support
Eli Lilly and Company: Grant/Research Support
Miltenyi Biotech: Honoraria
Seattle Genetics, Inc.: Honoraria

Shaji K. Kumar, MD 
AbbVie, Inc.: Grant/Research Support; Scientific Advisor
Amgen Inc.: Grant/Research Support; Scientific Advisor
BeiGene: Honoraria
Bristol-Myers Squibb Company: Grant/Research Support
CARsgen Therapeutics: Grant/Research Support
Celgene Corporation: Grant/Research Support; Scientific Advisor
Cellectar Biosciences: Consulting Fee
GeneCentrix, Inc.: Consulting Fee
Genentech, Inc.: Scientific Advisor
Janssen Pharmaceutica Products, LP: Grant/Research Support; Scientific Advisor
Kite Pharma: Grant/Research Support
MedImmune Inc.: Grant/Research Support; Scientific Advisor
Merck & Co., Inc.: Grant/Research Support
Novartis Pharmaceuticals Corporation: Grant/Research Support
Oncopeptides: Consulting Fee
Roche Laboratories, Inc.: Grant/Research Support
sanofi-aventis U.S.: Grant/Research Support; Scientific Advisor
Takeda Pharmaceuticals North America, Inc.: Grant/Research Support
TeneBio: Grant/Research Support

Daniel A. Pollyea, MD, MS
AbbVie, Inc.: Scientific Advisor
Amgen Inc.: Scientific Advisor
Bristol-Myers Squibb Company: Scientific Advisor
Celgene Corporation: Scientific Advisor
Genentech, Inc.: Scientific Advisor
GlycoMimetics, Inc. Scientific Advisor
Karyopharm Therapeutics: Scientific Advisor
Kiadis Pharma: Scientific Advisor
Novartis Pharmaceuticals Corporation: Scientific Advisor
Syndax Pharmaceuticals Inc.: Scientific Advisor
Syros Pharmaceuticals: Scientific Advisor
Takeda Pharmaceuticals North America, Inc.: Scientific Advisor

Stephen D. Smith, MD
Acerta Pharma: Grant/Research Support
AstraZeneca Pharmaceuticals LP: Consulting Fee; Grant/Research Support
*Ayala: Consulting Fee; Grant/Research Support
Bayer HealthCare: Grant/Research Support
BeiGene: Grant/Research Support; Scientific Advisor
*Bristol-Myers Squibb Company: Consulting Fee; Grant/Research Support
Denovo Biopharma: Consulting Fee; Grant/Research Support
Genentech, Inc.: Consulting Fee; Grant/Research Support
*Ignyta: Grant/Research Support
*Incyte Corporation: Grant/Research Support
Karyopharm Therapeutics: Consulting Fee
Kite Pharma: Consulting Fee
Merck & Co., Inc.: Grant/Research Support
Millennium Pharmaceuticals, Inc.: Consulting Fee
Pharmacyclics:Grant/Research Support 
Portola Pharmaceuticals, Inc.: Grant/Research Support
* signifies the relationship relates to the individual's spouse/partner

William G. Wierda, MD, PhD
AbbVie, Inc.: Grant/Research Support
AstraZeneca Pharmaceuticals LP/Acerta Pharma: Grant/Research Support
Celgene Corporation/Juno Therapeutics, Inc.: Grant/Research Support
Cyclacel Pharmaceuticals, Inc.: Grant/Research Support
Genentech, Inc.: Grant/Research Support
Gilead Sciences, Inc.: Grant/Research Support
GlaxoSmithKline/Novartis Pharmaceuticals Corporation: Grant/Research Support
Janssen Pharmaceutica Products, LP: Grant/Research Support
Kite Pharma: Grant/Research Support
Loxo Oncology, Inc.: Grant/Research Support
Oncternal Therapeutics, Inc.: Grant/Research Support
Pharmacylics: Grant/Research Support
Sunesis Pharmaceuticals, Inc.: Grant/Research Support
Xencor, Inc.: Grant/Research Support

Andrew D. Zelenetz, MD, PhD
AbbVie, Inc.: Scientific Advisor
Adaptive Biotechnologies Corporation: Consulting Fee
Amgen Inc: Consulting Fee
AstraZeneca Pharmaceuticals LP: Scientific Advisor
BeiGene: Grant/Research Support; Other Financial Benefit
Celgene Corporation: Consulting Fee
Genentech, Inc.: Scientific Advisor
Genentech, Inc./Roche Laboratories, Inc.: Consulting Fee
Gilead Sciences, Inc.: Consulting Fee; Grant/Research Support; Scientific Advisor
Janssen Pharmaceutica Products, LP: Consulting Fee
MEI Pharma Inc.: Grant/Research Support
MorphoSys AG: Scientific Advisor
Novartis Pharmaceuticals Corporation: Consulting Fee
Pharmacyclics: Scientific Advisor
Roche Laboratories, Inc.: Grant/Research Support
Verastem Oncology: Consulting Fee

NCCN Staff Disclosures

The NCCN Activity Planning staff listed below discloses no relevant financial relationships:
Michael Abrams; Melissa Esplen; Mark A. Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Lisa Perfidio, MS; Shannon Ryan, CMP; Kathy Ann Smith, CHCP; Sarah Weinstein

The NCCN Leadership listed below discloses no relevant financial relationships: 
Robert W. Carlson, MD; Gary J. Weyhmuller, MBA, SPHR 

The NCCN Leadership listed below discloses the following relevant financial relationships: 
Wui-Jin Koh, MD: IBM Watson Health for Oncology and Genomics; Scientific Advisor

The NCCN Clinical staff listed below discloses no relevant financial relationships:
Mary Anne Bergman; Marian Birkeland, PhD; Jennifer L. Burns, BS; Mary A. Dwyer, MS, CGC; Cindy Hochstetler, PhD; Liz Hollinger, RN, BSN; Jennifer Keller; Rashmi Kumar, PhD; Beth Lynn, RN, CMSRN; Ndiya Ogba, PhD; Hema Sundar, PhD 

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
NCCN designates this live activity for a maximum of 6.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 6.5 contact hours.

Pharmacists
NCCN designates this knowledge-based continuing education activity for 6.5 contact hours (0.65 CEUs) of continuing education credit. UAN: JA4008196-0000-20-095-L01-P

Physician Assistants
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 6.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

American Board of Internal Medicine Maintenance of Certification (MOC)


Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.5 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Aggregated participant data will be shared with the commercial supporters of this activity.

American Board of Pathology Maintenance of Certification (MOC)


This activity has been registered to offer credit in the American Board of Pathology’s (ABPath) Maintenance of Certification program. Participants may earn up to 6.5 Lifelong Learning (Part II) credits.

Aggregated participant data will be shared with the commercial supporters of this activity.

American Board of Medical Specialties Maintenance of Certification (MOC)
Through the American Board of Medical Specialties (“ABMS”) ongoing commitment to increase access to practice relevant Maintenance of Certification (“MOC”) Activities through the ABMS Continuing Certification Directory, the NCCN 2020 Annual Congress: Hematologic Malignancies has met the requirements as a MOC Part II CME Activity (apply toward general CME requirement) by the following ABMS Member Boards:

MOC Part II CME Activity
Radiology

Available Credit

  • 6.50 AAPA Category 1 CME credit
  • 6.50 ABIM MOC
  • 6.50 ACPE contact hours
  • 6.50 AMA PRA Category 1 Credit™
  • 6.50 ANCC contact hours
  • 6.50 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Click the Take Course button to start the credit claiming process.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection
  • Adobe Reader or other PDF reader software for certificate viewing/printing